v3.26.1
Consolidated Statements of Cash Flows - USD ($)
 6 Months Ended 12 Months Ended
Nov. 30, 2025
Nov. 30, 2024
Dec. 31, 2025
May 31, 2025
Dec. 31, 2024
May 31, 2024
Dec. 31, 2023
Cash flows from operating activities              
Net loss     $ (1,376,430)   $ (4,157,737)   $ (4,340,975)
Adjustments to reconcile net loss to net cash used in operating activities              
Amortization and depreciation       255,046   1,125,254
Issuance cost in relation to warrant     153,189    
Change in fair value of warrant liability     (690,000)    
Share-based compensation         1,265,189
Loss on investments in marketable securities, net         9,266
Unrealized loss (gain) from fair value change of the long-term investments, net         (6,431,088)
Impairment loss of long-term investment       1,000,000   77,200
(Gain) loss on disposal of long-lived assets       (58,621)   110,852
Impairment loss on long-lived assets       1,699,481   750,381
Allowance for credit loss of due from a related party         521,007
Write-off of prepayment and other receivables       45,677   62,369
Write-off of accounts receivable       6,280  
Write-down of inventories         13,206
Gain on disposal of subsidiaries       (703)  
Amortization of right-of-use assets       50,520   252,345
Interest expense and accretion of convertible debts     180,000   180,000   45,266
Reversal of deferred cash bonus         (1,646,228)
Changes in operating assets and liabilities              
Accounts receivable       41,349   126,717
Inventories         14,516
Other receivables and prepayments     17,506   291,078   227,457
Long-term deposits         29,106
Amounts due from related parties       961   63,050
Amounts due to related parties     (464)   464   (8,524)
Accounts payable and accrued expenses     (28,368)   (422,705)   398,635
Operating lease liabilities     (91,979)   (120,824)   (389,365)
Net cash used in operating activities     (1,836,546)   (1,189,734)   (7,724,364)
Cash flows from investing activities              
Purchases of property and equipment         (3,015)
Proceeds from disposal of property and equipment       58,621   15,385
Proceeds from sales of investment securities         93,215
Loan to a related party         (92,459)
Repayment of loan and interest from a related party         611,641
Net cash provided by investing activities       58,621   624,767
Cash flows from financing activities              
Loan from related parties         2,500,000
Proceeds from issuance of Class A Ordinary Shares, and warrant     2,000,000     1,575,562
Exercise of share options             16,506
Payments related to offering costs     (284,001)    
Repayment of bank loan         (3,000,000)
Proceeds from issuance of convertible notes         3,000,000
Proceeds from issuance of Class A Ordinary Shares     3,070,000    
Payments related to offering costs     (370,800)    
Net cash provided by financing activities     4,415,199     4,092,068
Net increase (decrease) in cash     2,578,653   (1,131,113)   (3,007,529)
Cash and cash equivalents – Beginning of year     874,238   2,005,351   5,012,880
Cash and cash equivalents – End of year     3,452,891   874,238   2,005,351
Supplemental disclosures of cash flow information              
Interest paid         94,108
Non-cash operating, investing and financing activities              
Reclassification of placement agent warrant redemption amount     47,000    
Right-of-use assets obtained in exchange for new operating lease liabilities         338,525
Convertible notes converted to Class A Ordinary Shares         6,000,000
Settlement of deferred cash bonus by issuance of share options       $ 451,660   $ 3,078,196
DiamiR Biosciences Corp              
Cash flows from operating activities              
Net loss $ (409,955) $ (282,532)   $ (743,235)   $ (614,405)  
Reconciliation of net loss to net cash used in operating activities:              
Deferred offering costs expensed       150,526    
Noncash lease expense 18,925 18,378   (1,830)   (8,450)  
Amortization of note discount 31,550 19,349   43,538   25,367  
Adjustments to reconcile net loss to net cash used in operating activities              
Amortization and depreciation 9,772 10,155   20,828   20,052  
Share-based compensation 20,418   24,312   194,846  
Changes in operating assets and liabilities              
Accounts receivable (131,091) 85,086   89,281   (89,281)  
Prepaid expenses 40,945 (36,514)   (77,036)   (89,334)  
Accounts payable and accrued expenses 441,538 12,941   83,210   108,997  
Accrued interest 25,607 15,617   34,634   23,232  
Deferred revenue (43,982)   43,982    
Income taxes payable (176,002) 9,445   16,483   112,947  
Operating lease liabilities (22,315) (18,204)   1,867   7,115  
Net cash used in operating activities (215,008) (145,861)   (313,440)   (308,914)  
Cash flows from investing activities              
Purchases of property and equipment (6,938)     (1,278)  
Net cash provided by investing activities (6,938)     (1,278)  
Cash flows from financing activities              
Proceeds from notes payable 250,000 200,000   300,000   200,000  
Net cash provided by financing activities 250,000 200,000   300,000   200,000  
Net increase (decrease) in cash 28,054 54,139   (13,440)   (110,192)  
Cash and cash equivalents – Beginning of year 56,836 70,276   70,276   180,468  
Cash and cash equivalents – End of year 84,890 124,415   56,836   70,276  
Non-cash investing and financing activities:              
Discounts on note payable to founder 12,694 24,970   34,692   35,063  
Supplemental disclosures of cash flow information              
Interest paid      
Cash paid for taxes   $ 1,456   $ 1,456